Desmoid tumor differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 19: Line 19:
***[[Secondary]] to certain [[drugs]]
***[[Secondary]] to certain [[drugs]]
***Underlying [[malignancy]] such as [[lymphoma]]
***Underlying [[malignancy]] such as [[lymphoma]]
*Furthermore, [[desmoid tumor]]<nowiki/>s must be differentiated from:
*Furthermore, generally all [[desmoid tumors]]<nowiki/>s must be differentiated from:
**Acute [[hematoma]]
**Acute [[hematoma]]
**[[Lymphoma]]
**[[Lymphoma]]
Line 31: Line 31:
**[[Primitive neuroectodermal tumor]]
**[[Primitive neuroectodermal tumor]]
{| class="wikitable"
{| class="wikitable"
|+
|+ ''' Differentiating desmoid tumor from other diseases'''
!Disease entity
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease entity
!Etiology (Genetic or others)
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Etiology (Genetic or others)
!Histopathological findings
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological findings
!Immunohistochemical staining
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Immunohistochemical staining
!Benign/Malignant
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Benign/Malignant
!Risk factors
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors
!Common site of involvement
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Common site of involvement
!Clinical manifestations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
!Other associated findings
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other associated features
|-
|-
|[[Desmoid tumor|'''Desmoid tumor''']]
|[[Desmoid tumor|'''Desmoid tumor''']]

Revision as of 20:58, 12 March 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Extra-abdominal desmoid tumor must be differentiated from fibrosarcoma, low-grade fibromyxoid sarcoma and Gardner fibroma. Intra-abdominal desmoid tumor must be differentiated from gastrointestinal stromal tumor (GIST), benign fibrous tumor/solitary fibrous tumor (SFT), inflammatory myofibroblastic tumor (IMT), sclerosing mesenteritis and retroperitoneal fibrosis. Furthermore, generally all desmoid tumors must be differentiated from acute hematoma, lymphoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, neurofibroma, nodular fasciitis, hypertrophic scars, keloids and primitive neuroectodermal tumor.

Differentiating Desmoid tumor from other Diseases

Differentiating desmoid tumor from other diseases
Disease entity Etiology (Genetic or others) Histopathological findings Immunohistochemical staining Benign/Malignant Risk factors Common site of involvement Clinical manifestations Other associated features
Desmoid tumor Sporadic desmoids are associated with following mutations:
  • Wnt/beta-catenin signaling pathway
  • Mutations in CTNNB1 (Beta-catenin gene) (85%)
  • APC gene mutations (10-15%)

Familial desmoids/Hereditary desmoid disease is associated with:

  • Mutation in second copy of APC gene

Pediatric desmoids have following additional mutations involving:

  • AKT1 E17K (31%)
  • BRAF V600E (19%)
  • TP53 R273H (9%)
Histologically, desmoid tumors consist of:
  • Linearly arranged elongated fibroblasts and myofibroblasts
  • Characterized by elongated, tapered cytoplasm; elongated, vesicular, typical-appearing nuclei; and multiple small nucleoli
  • Surrounded and separated from each other by collagen
Positive for:
  • Nuclear beta-catenin (90%)
  • Vimentin
  • Alpha smooth muscle actin
  • Muscle actin

Negative for:

  • Desmin
  • Cytokeratins
  • S-100
  • c-KIT
  • Benign
  • High local aggressive infiltration
  • High local recurrence
  • Familial adenomatous polyposis (FAP)
  • Gardner syndrome (inherited desmoids)
  • Turcot syndrome
  • Specific location of APC (adenomatous polyposis coli) gene mutation i.e. 3' end of the APC gene, specifically between codons 1445 and 1580
  • Family history of desmoid tumor
  • Family history of colon cancer/FAP
  • Estrogen therapy
  • Oral contraceptive pills
  • Pregnancy
  • History of antecedent surgical/accidental trauma at the tumor site (30%)
  • History of breast cancer
  • History of repeated irradiation to a certain body part
  • Female gender
  • Sex hormones/androgens
  • Abdominal wall (intra-abdominal desmoids)
  • Extra-abdominal desmoids may involve:
    • Shoulder girdle
    • Upper arms
    • Upper legs
    • Hip/buttock region
    • Trunk
    • Head
    • Neck
    • Breast (history of breast cancer/breast surgery
  • Intra-abdominal desmoids may involve:
    • Mesentery
    • Retroperitoneum
    • Bowel
  • Asymptomatic
  • Painless/painful lump in affected area
  • Pain or soreness caused by compressed nerves or muscles
  • Limping or other difficulty using the legs, feet, arms or hands
  • Decreased movement or range of motion
  • Nausea
  • Vomiting
  • Breast mass (in case of breast desmoids)
  • Loss of sleep
  • Anxiety
  • Abdominal mass/pain
  • Constipation
  • Bloating
  • Intestinal rupture
  • Rectal bleeding
  • Compression of kidneys, ureters, mesenteric vessels and vena cava
Desmoids may be associated with following:
  • Other sporadic tumors such as:
    • Dupuytren's contracture
    • Plantar fibrosis
    • Peyronie's disease
    • Carpal tunnel syndrome
    • Infantile fibrosarcoma
    • Fibrous dysplasia
  • Trisomy 8
  • Trisomy 20
Fibrosarcoma/Fibroblastic sarcoma
  • Unknown precise cause
  • Genetics may play a role
  • Tumor cells resemble mature fibroblasts (spindle-shaped), secreting collagen, with rare mitoses
  • Spliting and merging cells arranged in short fascicles giving "fish bone" appearnace
  • Immature blood vessels (lacking endothelial cells) favor the bloodstream metastasizing
  • "Herringbone" pattern of cell arrangement
Strongly positive for:
  • Vimentin

Negative for:

  • Desmin
  • Smooth muscle actin
  • HHF-35
  • Osteocalcin
  • CD-68
  • LCA
  • s100
  • HMB-45
  • CD-31
  • CD-34
  • Cytokeratin
  • Epithelial membrane antigen
  • CD-99
  • Malignant (with metastatic potential)
  • Familial adenomatous polyposis
  • Li-Fraumeni syndrome
  • Neurofibromatosis type 1
  • Nevoid basal cell carcinoma syndrome
  • Retinoblastoma
  • Tuberous sclerosis
  • Werner syndrome
  • Giant cell tumor
  • Enchondroma
  • Fibrous dysplasia
  • Bizarre parosteal osteochondromatous proliferation
  • Chronic osteomyelitis
  • Paget's disease
  • Radiation therapy
  • Surgically treated fracture
  • Bone infarction
  • Exposure to certain chemicals, such as thorium dioxide, vinyl chloride, or arsenic
  • Lymphedema, a swelling in the arms and legs
Primary bone malignancy involving end of long bones:
  • Upper end of tibia
  • Lower end of femur
  • Localized Pain
  • Swelling
  • Loss of range of motion
  • Pain with weight-bearing
  • Night pain
  • Pathologic fracture of affected bone
  • Moth-eaten appearance on Xray
Low-grade fibromyxoid sarcoma[4][5][9][10][11][12][13][14] Translocation:
  • t(7;18;16) or
  • t(7;16) (q34:p11)

Fusion gene:

  • FUS/CREB3 L2 (76%-96%)
  • FUS/CREB3 L1 (4%-6%)
  • Low to moderate cellularity
  • Regular medium sized nuclei
  • Loosely arranged fascicles of bland spindle cells (whorling pattern)
  • Loose myxoid stroma
  • No cellular atypia
  • Hypocellular/myxoid areas in nodules merging with collagenised areas
Positive for:
  • MUC4 (highly specific and sensitive)
  • Vimentin

Occasionally positive for:

  • Desmin
  • SMA
  • EMA
  • CD34

Negative for:

  • Keratin
  • Actin
  • S100
  • Epithelial membrane antigen
  • CD31
  • CD68
  • Cytokeratin
  • (AE1/AE3)
  • Leu-7
  • Neuron-specific enolase
  • Benign (histological appearance)
  • High metastasizing potential/local aggressive infiltration
  • High local recurrence
_
Majority occurring in subfascial location and rarely involving subcutis or dermis in following sites:
  • Lower extremities
  • Trunk
  • Groin
  • Upper extremities
  • Thorax
  • Buttocks
  • Abdominal wall
  • Maxillofacial region (rarely)
  • Painless, slow-growing well-circumscribed mass
  • Average size-5cm (ranges from 1-20cm)
_
Benign fibrous tumor/Solitary fibrous tumor (SFT) [15][16][17][18][19][20][21][22][23] Intra-chromosomal inversion at:
  • Chromosome 12q13 leading to formation of NAB2–STAT6 chimeric fusion gene (highly variable breakpoints)

TERT promoter mutations responsible for:

  • High aggressive potential
  • Metastatic potential
  • Fibroblast-like tumor cells arranged in a “patternless” pattern
  • Collagenous stroma with staghorn, hyalinized blood vessels
  • Increased mitotic activity
  • Hypercellularity
  • Nuclear atypia
  • Pleomorphism
  • Lipomatous, myxoid, or dedifferentiated variants
Positive for:
  • CD34
  • Vimentin
  • CD99 (013)
  • Bcl-2

In few cases, positive for:

  • Focal keratin reactivity
  • Focal desmin reactivity

Negative for:

  • CD31
  • Cytokeratin
  • Glial fibrillary acidic protein
  • Smooth muscle actin
  • S-100 protein
  • Epithelial membrane antigen
  • Metastasis(10%-20%)
  • Recurrence (10%-20%)
_
  • Any anatomic site
  • Serosal membranes such as:
    • Pleura (most common site)
    • Dura of the meninges
    • Peritoneum (or peritoneal cavity)
  • Thoracic cavity (mediastinum, lung parenchyma)
  • Intra-abdominal SFTs involve:
    • Retroperitoneal soft tissue (most common)
    • Liver
    • Diaphragm
    • Pelvis visceras (bladder, prostate, seminal vesicle, kidney)
  • Head and neck sites include:
    • sinonasal tract
    • oral cavity
    • orbit
    • buccal mucosa
    • tongue
    • lower lip
  • Extremities
  • Skin (dermis)
  • Bone
  • Asymptomatic
  • Pulmonary symptoms (cough, shortness of breath, chest pain, hemoptysis, obstructive pneumonitis because of airway obstruction)
  • Intra-abdominal symptoms (pain,weight loss, dysuria, urinary retention, hydronephrosis, nocturia, constipation, incontinence, vomiting)
  • Paresthesias
  • Symptoms due to nerve impingement
  • Meningeal symptoms
  • Hypoglycemia (due to paraneoplastic syndromes)
  • Symptoms due to hypertrophic pulmonary osteoarthropathy include:
    • Clubbing of the fingers
    • Periostitis
    • Synovial effusions
Paraneoplastic syndromes associated with SFTs include:
  • Doege-Potter syndrome (Refractory hypoglycemia due to IGF2, associated with large peritoneal/pleural tumors)
  • Hypertrophic pulmonary osteoarthropathy (HPO)/Pierre-Marie-Bamberger syndrome( in pleuropulmonary SFTs, secretes hyaluronic acid, cytokines)
Gardner fibroma/Gardner-associated fibroma (GAF)[24][25][6][26]
  • APC gene mutation
  • Thick haphazardly arranged collagen bundles (greater abundance of collagen)
  • Few interspersed spindle cells of fibroblast type (less cellularity)
Positive for:
  • Nuclear Beta-catenin (highly positive)
  • CD34
  • Cyclin-D1
  • C-myc
  • Benign
  • Gardner-type familial adenomatous polyposis
  • Germline mutations in APC gene
  • Inherited desmoids
  • Gardner syndrome
  • The presence of nuchal-type fibroma may indicate Gardner Fibroma, when seen in children
Any part of body:
  • Back (most common)
  • Paraspinal region (most common)
  • Chest wall
  • Abdomen
  • Head
  • Neck
  • Arms
  • Legs
  • Firm rubbery mass (not a well-circumscribed)
  • Size from 1-10 cm
  • Signs and symptoms due to associated FAP or Gardner syndrome
  • Precursor lesion for desmoid (50% cases) with a more cellular appearance
  • Precursor lesion for colonic adenomas in asymptomatic FAP patients
Gastrointestinal stromal tumor (GIST)[27][28][29][30][31] Activating mutation of:

Pediatric GISTs (SDH-deficient) have mutations of one of the:

  • SDH (succinate dehydrogenase)gene subunits

GIST as a part of Carney triad has following mutation:

  • Hypermethylation of the SDHC promoter causing epigenetic inactivation of the SDHC gene

Wild-type GISTs have following three molecular subtypes:

  • DHX mutations (66%)
  • SDHC promoter hypermethylation (22%)
  • SDH competent (12%) which can further be broken into:
    • NF1 mutations
    • BRAF V600E mutations
    • Other rare mutations or fusions
    • No identified abnormality
GIST cells basically arise from interstitial cells of Cajal (ICCs) and appear as follows on histology:
  • Spindle cells (60%-80%):
    • Fascicular or whorled like appearance
    • Multiple compact cells with minimal stroma
    • Eosinophilic, basophilic or amphophilic cytoplasm
  • Epithelioid cells (20%-30%)
    • Clearly defined with an abundant amphophiliccytoplasm
  • Pleomorphic/mixed cells (occasionally, 10%)
    • Both spindle or epitheloid cells
Positive for:
  • CD117 (overexpression of the receptor tyrosine kinase KIT is the most prominent diagnostic test)
  • CD34
  • DOG-1
  • PKC-theta (protein kinase C theta)

Consistently negative for:

  • Beta-catenin
  • Malignant potential (esophageal and colonal GIST)
  • Metastasis (to liver, lungs, bones, subcutis, spleen)
  • Age group of 50-80years
  • Primary familial GIST syndrome
  • Neurofibromatosis type 1 (NF1)
  • Carney-Stratakis syndrome (dyad of GISTs and paragangliomas)
  • Carney triad (GIST, paraganglioma, and pulmonary chondromas)
  • Urticaria pigmentosa
Can involve any part of GIT:
  • Stomach (most common)
  • Duodenum
  • Omentum
  • Mesentery
  • Esophagus
  • Colon
  • Peritoneum
Depending on tumor size and localization in GIT:
Inflammatory myofibroblastic tumor (IMT)[32][33][34][35][36][37][38][39][33][36][7] Unknown underlying etiology, may be due to inflammatory reaction to:
  • Infection
  • Underlying low grade malignancy

Mutations such as:

  • ALK (anaplastic lymphoma kinase) gene mutations in the tyrosine kinase locus at band 2p23
  • Spindle to stellate-shaped cells
  • Spindle cells arranged in short fascicles with a focal storiform (whorled or cartwheel-like) architecture
  • Spindle cells show features of fibroblasts and myofibroblasts
  • Variably dense, chronic, mixed polymorphic infiltrate of mononuclear inflammatory (plasma cells and lymphocytes, histiocytes, neutrophils, and occasional eosinophils)
  • Histiocytes have multinucleated forms with finely vacuolated cytoplasmic lipid droplets
  • Plasma cells with cytoplasmic Russell bodies (globular cytoplasmic inclusions of immunoglobulin) and polyclonal pattern of light chain expression
  • Absent hyperchromasia and atypical mitoses
Positive for:
  • IG+ (plasma cells)
  • IL-1
  • IL-6
  • Smooth muscle actin
  • Desmin
  • Calponin
  • Activin-like kinase 1

Negative for:

  • Beta-catenin
  • Metastatic
  • Multiorgan disease in association with chronic persistent Eikenella corrodens infection
  • Epstein Barr virus infection
  • Human herpes virus (HHV)-8 infection (Kaposi's sarcoma, multicentric Castleman's disease)
  • Lungs
  • Gastrointestinal system
  • Pelvic region
    • Bladder
    • Uterus
  • Retroperitoneum
  • Skin
  • Bone (femur, temporal bone, jaw bone)
  • CNS
  • Soft tissues
  • Larynx
  • Heart (right ventricle is most commonly involved)
  • Pancreas (rarely)
  • Asymptomatic (70%)
  • Painless asymptomatic mass/lump/swelling
  • Pulmonary IMT presents as:
    • Chest pain
    • Cough
    • Dyspnea
    • Hemoptysis (recurrent)
    • Fever
    • Fatigue
    • Weight loss
    • Appetite loss
  • Bone IMT presents with:
    • Mild bone pain
    • Easy fractures
    • Headache
    • Dizziness
    • Numbness at tumor site
    • Bone marrow involvement in some cases
  • Heart IMT presents with:
    • Chest pain
    • Difficulty breathing
    • Palpitations
    • Fainting
    • Obstruction of blood flow in the heart (large tumors)
  • Bladder IMT presents with:
    • Painless hematuria
    • Chronic pelvic pain
    • Difficulty in urinating
    • Presence of burning sensation
  • CNS IMT presents with:
    • Presence of solitary or multiple tumors at various locations in the brain
    • Recurrent headaches
    • Headache
    • Nausea and vomiting
    • Blurred vision
    • Double vision
    • Drooping of the eyelid
    • Dizziness
    • Back pain (if spine involved)
    • Seizures
Also known as:
  • Pseudo-inflammatory tumors
  • Inflammatory pseudotumor
  • Plasma cell granuloma
  • Inflammatory pseudotumor
  • Fibrous histiocytoma
  • Fibroxanthoma
  • Xanthogranuloma
  • Inflammatory pseudosarcoma
  • Atypical fibromyxoid tumor
  • Atypical myfibroblastic tumor
Sclerosing mesenteritis[40][41][42][43][44][45][46][47][48][49][50][51][52]

[53][54][55][56][57][58][59][60]

Unknown exact etiology:
  • Encompasses a spectrum of idiopathic primary inflammatory and fibrotic processes affecting mesentery
Varying components of:
  • Inflammation, fibrosis, and fat necrosis
  • Adipocyte necrosis (mesenteric lipodystrophy)
  • Chronic inflammatory state (mesenteric panniculitis)
  • Fibrosis (sclerosing mesenteritis)
_
  • Non-neoplastic inflammatory and fibrotic disease
  • Abdominal surgery/trauma:
    • Cholecystectomy
    • Appendectomy
    • Hysterectomy
    • Colectomy
    • Pneumatic jackhammer
    • Occult ileal perforation
  • Autoimmunity:
    • Riedel thyroiditis
    • Primary sclerosing cholangitis
    • Retroperitoneal fibrosis
    • Orbital pseudotumor
    • Autoimmune hemolytic anemia
    • Minimal change nephropathy
    • Systemic lupus erythematosus
    • Relapsing polychondritis
    • Multifocal fibrosclerosis
    • Limited systemic sclerosis
    • Celiac-associated T-cell lymphoma
  • Paraneoplastic syndrome:
    • Non-Hodgkin lymphoma(most common)
    • Breast cancer
    • Carcinoid
    • Melanoma
    • Squamous carcinoma and adenocarcinoma of the lung
    • Renal carcinoma
    • Multiple myeloma
    • Hepatocellular carcinoma
    • Prostate adenocarcinoma
    • Ovarian carcinoma
    • Endometrial carcinoma
    • Cervical carcinoma
    • Angiosarcoma
    • Gastrointestinal adenocarcinomas
  • Ischemia and infection history:
    • Typhoid fever
    • Dysentery
    • Tuberculosis
    • Syphilis
    • Malaria
    • Influenza
    • Rheumatic fever
  • Mesentery
  • Asymptomatic
  • Abdominal pain
  • Nausea and vomiting
  • Altered bowel habits (Constipation or diarrhea)
  • Weight loss
  • Fever
  • Malaise
  • Abdominal tenderness
  • Abdominal distension
  • Peritoneal inflammation and ascites (usually chylous)
  • Pleural effusion
  • Protein-losing enteropathy (Fever, edema)
  • Biliary obstruction (hemolytic anemia, jaundice)
  • Bowel obstruction
  • Obstructive uropathy/renal failure
  • Chylous ascites
  • Chronic mesenteric ischemia
  • Anemia
  • Hypoalbuminemia
  • Mesenteric vascular occlusion (both arterial and venous)
Nomenclature used in the medical literature for idiopathic primary inflammatory and fibrotic processes of the mesentery is as follows:
  • Mesenteric lipodystrophy (predominant fat necrosis predominance)
  • Mesenteric fibrosis
  • Mesenteric panniculitis
  • Mesenteric lipodystrophy
  • Retractile mesenteritis
  • Mesenteric Weber-Christian disease
  • Xanthogranulomatous mesenteritis
  • Mesenteric lipogranuloma
  • Liposclerotic mesenteritis
  • Inflammatory pseudotumor
  • Isolated lipodystrophy
  • Retroperitoneal xanthogranuloma
Retroperitoneal fibrosis[61][62][63][64][65][66][67][68][69][70][71][72][73]

Idiopathic (70%) [Ormond's disease] is an immune-mediated disease caused by:

  • Other autoimmune diseases
  • Immunoglobulin G4-related disease (IgG4-RD)
  • Chronic periaortitis
  • Allele HLA‑DRB1*03, D32 polymorphism of the gene encoding CCR5 (chemokine receptor)
  • TTCCAT haplotype of the gene encoding CCL11/eotaxin‑1 (drives the recruitment of eosinophils)

Secondary to:

Fibro-inflammatory disease histologically hallmarked by fibrous tissue and chronic inflammation:
  • Fibrous tissue composed of extracellular matrix containing type I collagen fibers organized in thick irregular bundles, often encircling small retroperitoneal vessels
  • Fibroblasts:
    • Show signs of activation and transition into myofibroblasts (α‑smooth muscle actin expression)
    • Are major source of collagen production
    • Rarely show mitoses, undergo clonal proliferation
  • Inflammatory infiltrate consists of numerous lymphocytes, plasma cells, and macrophages
  • Inflammatory cells maybe:
    • Interspersed within the collagen bundles (“diffuse” pattern) or
    • Organized in nodular aggregates, usually around small vessels, having a B cell core surrounded by CD4+ T cells
  • When IgG4+/total IgG+ plasma cell ratio is >40%, RPF is classified as “IgG4-related” if other features such as storiform fibrosis, eosinophil infiltration, and obliterative phlebitis are also present
  • Tryptase positive (mast cells)
  • Benign immune mediated inflammatory process
  • Idiopathic [Ormond's disease]
  • Secondary to certain drugs (ergot-derivatives, methysergide, bromocriptine, beta blockers, methyldopa, hydralazine, analgesics)
  • Biological agents (etanercept, infliximab)
  • Underlying malignancy (carcinoid, Hodgkin and non-Hodgkin lymphoma, sarcomas, colorectal, breast, prostate and bladder carcinoma)
  • Infections (tuberculosis, histoplasmosis, actinomycosis)
  • Radiation therapy for testicular seminoma, colon and pancreatic cancer
  • Retroperitoneal hemorrhage
  • Surgery (lymphadenectomy, colectomy, aortic aneurysmectomy)
  • Secondary (AA) amyloidosis
  • Trauma
  • Barium enema
  • Mesenteric panniculitis
  • Different forms of histiocytosis particularly Erdheim-Chester disease
  • Exposure to asbestos
  • Tobacco smoke exposure
  • Thoracic aorta
  • Mesenteric arteries
  • Renal arteries and veins
  • Epiaortic arteries
  • Ureters
  • Abdominal organs
  • Pancreas
  • Salivary glands
  • Lymph nodes
  • Pituitary gland
  • Pain in the lower back, abdomen, or flank (most common presentation, bilateral or unilateral flank pain that radiates to the inguinal region, or acute onset pain similar to renal colic)
  • Abdominal aortic aneurysms
  • Malaise
  • Anorexia
  • Weight loss
  • Fever
  • Nausea and vomiting
  • Testicular pain
  • Constipation
  • Venous compression (inferior vena cava) leading to:
    • Lower limb edema (lymphatic compression)
    • Inferior vena cava syndrome
    • Deep vein thrombosis
    • Pulmonary embolism
  • Arterial stenosis (rare) causing:
    • Upper-leg claudication
    • Mesenteric ischemia (mesenteric arteries compression)
    • Thoracic aorta and/or the epi-aortic arteries' compression
  • Recurrent laryngeal nerve paralysis causing hoarsness and dry cough
  • Acute kidney injury (AKI) (due to bilateral encasement of ureteral and renal involvement in peri-iliac retroperitoneal fibrosis)
  • Renal atrophy (due to previous transient unilateral obstruction or renal artery stenosis)
  • Obstructive uropathy
  • Gross hematuria
  • Urinary symptomes (urinary urgency,frequency, and dysuria)
  • Hypertension (due to renal artery impingement)
  • Obstruction of the inferior vena cava and/or iliac veins
  • Thrombophlebitis
  • Deep vein thrombosis
  • Varicocele
  • Hydrocele
Retroperitoneal fibrosis is also known as:
  • Ormond's disease
  • Periureteritis fibrosa
  • Periureteritis plastica
  • Chronic periureteritis
  • Sclerosing retroperitoneal granuloma
  • Fibrous retroperitonitis
Lymphoma
  • Diffuse large B cell lymphoma (DLBCL):
    • Rare MALT1 rearrangements, trisomy 18 in some, possible NFκB activation in minority
  • Extranodal marginal B cell lymphoma arising from mucosal associated lymphoid tissue (MALT lymphoma):
    • Clonal rearrangements of immunoglobulin genes
    • Often trisomy of 3, 12, 18
    • Usually negative for characteristic MALT1 rearrangements t(11;18)(q21;q21) and t(14;18)(q32;q21)
  • Follicular lymphoma:
    • Presence of t(14;18)(q32;q21) translocation has not been systematically assessed in primary breast follicular lymphoma
  • Burkitt lymphoma:
    • t(8;14)(q24;q32) c-Myc and IgH translocation is most frequent
    • t(2;8)(p12;q24) IgΚ and c-Myc
    • t(8;22)(q24;q11) c-Myc and Igλ
Diffuse large B cell lymphoma (DLBCL):
  • Diffuse infiltration by large lymphoid cells, centroblastic > immunoblastic, activated B cell type > germinal center type

Extranodal marginal B cell lymphoma:

  • Vaguely nodular growth pattern, neoplastic cells occupy the marginal zone surrounding the B cell follicle mantle zone but can have diffuse growth pattern if follicles infiltrated / replaced
  • Marginal zone B cells, variable plasma cells, reactive follicles (±)
  • Monocytoid-like cells
  • Plasmacytic differentiation
  • Low mitotic rate

Follicular lymphoma:

  • Follicular and diffuse architectural patterns
  • Monotonous population of small cleaved cells (centrocytes)
  • Variable numbers of centroblasts (large noncleaved cells)
  • Associated sclerosis can cause single file infiltration pattern

Burkitt lymphoma:

  • Sheets of uniform medium sized lymphocytes with round nuclei, multiple basophilic nucleoli, course chromatin, scant to moderate basophilic cytoplasm, minimal intervening stroma
  • High mitotic rate
  • Tingible body macrophages containing apoptotic debris produce a "starry sky" appearance
  • Mantle cell lymphoma:
  • Small to medium sized, slightly irregular cells with scant cytoplasm
  • Classic Hodgkin lymphoma:
  • Reed-Sternberg cells and variants in a reactive background
  • Nodular lymphocyte predominant Hodgkin lymphoma:
  • Vague nodules of small B cells and interspersed large tumor cells (LP cells) with thin nuclear membranes, fine chromatin and variable nucleoli
  • MALT lymphoma:
    • Infiltration of thyroid epithelium creates lymphoepithelial lesions (lymphocytes "stuff" glandular lumina)
    • May have background lymphocytic thyroiditis
Positive for:
  • Diffuse large B cell lymphoma (DLBCL):
    • CD45, CD20, CD79a, PAX5, BCL2, Ki67 (high)
    • Activated B cell type (CD10-, BCL6- or CD10-, BCL6+, MUM1 / IRF+) is more common
    • Germinal center type (CD10+, BCL6+ or CD10-, BCL6+, MUM1 / IRF-)
    • Surface Ig+
    • CD43±
  • Extranodal marginal B cell lymphoma arising from mucosal associated lymphoid tissue (MALT lymphoma):
    • Surface and cytoplasmic Ig+ (IgM > IgG or IgA)
    • CD45, CD20, CD79a, PAX5, variable CD43, variable BCL2, Ki67 (low)
    • Variable monotypic cytoplasmic immunoglobulin seen in cases with plasmacytic differentiation
    • CD21 and CD23 highlight expanded / disrupted follicular dendritic meshworks
    • CD43±
  • Follicular lymphoma:
    • Surface Ig+
    • CD45, CD20, CD79a, CD10, BCL6, BCL2
    • CD21 and CD23 highlight follicular dendritic cell meshworks
  • Burkitt lymphoma:
    • Surface IgM+
    • CD45, CD20, CD79a, PAX5, CD10, BCL6, Ki67 (~100%)
    • Mantle cell lymphoma:
    • Surface IgMD+, CD20+, CD5+, CD10-, CD43+, cyclin D1+
    • Classic Hodgkin lymphoma:
    • R-S cells: CD30+, CD15±, PAX5+
    • Nodular lymphocyte predominant Hodgkin lymphoma:
    • LP cells: CD45+, CD20+
    • Thyroid MALT lymphoma:
    • CD20
    • Keratin
    • Thyroglobulin
    • CD45
    • Anaplastic large T cell lymphoma:
    • CD3, CD10, CD30, CD43, CD99, TdT
    • PreT lymphoblastic lymphoma:
    • CD3, CD10, CD99, TdT

Negative for:

  • Diffuse large B cell lymphoma (DLBCL):
  • EBER
  • Extranodal marginal B cell lymphoma, MALT type:
  • CD5, CD10, CD23, BCL6, cyclin D1
  • Follicular lymphoma:
  • CD5, CD23, cyclin D1
  • Burkitt lymphoma:
  • CD5, CD23, TdT, BCL2
  • Mantle cell lymphoma:
  • CD10-
  • Classic Hodgkin lymphoma:
  • R-S cells: ALK-, CD45-, CD3-
  • Nodular lymphocyte predominant Hodgkin lymphoma:
  • LP cells: CD15-, CD30-
  • Anaplastic large T cell lymphoma:
  • ALK1, bcl6
  • PreT lymphoblastic lymphoma:
  • bcl6-
  • Malignant
  • MALT lymphoma (Extranodal marginal B cell lymphoma may arise from it)
  • Underlying autoimmune disease
  • EBV (endemic and sporadic Burkitt lymphoma)
  • HIV (immunodeficiency associated Burkitt lymphoma)
  • HHV8
  • Chronic hepatitis C infection
  • Transplants
  • Chemotherapy
Anywhere in body
  • Lymph nodes
  • Esophagus
  • Bladder
  • Bone
  • Oral cavity
  • Thyroid gland
  • Painless palpable mass, with or without ipsilateral lymphadenopathy
  • Fever
  • Night sweats
  • Weight loss
  • Neck mass
  • Dysphagia
  • Odynophagia
  • Chest / abdominal pain
  • Weight loss
  • Hemorrhage
  • Vocal cord paralysis / hoarseness
  • Stricture / obstruction
  • Perforation with esophagomediastinal or esophagotracheobronchial fistula or mediastinitis
  • Vocal cord paralysis
  • Cold nodule
WHO classification of lymphoma:
  • Hodgkin lymphomas arise from precursor B cells (Reed-Sternberg cells)
    • Classic Hodgkin lymphoma (CHL) - 95% is further subclassified as:
      • Nodular sclerosis
      • Lymphocyte rich
      • Mixed cellularity
      • Lymphocyte depleted
    • Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) - 5%
  • Non-Hodgkin lymphomas arise from monoclonal expansion of malignant B or T cells
    • B cell lymphomas
      • B cell acute lymphoblastic lymphoma (ALL)
      • Chronic lymphocytic lymphoma / small lymphocytic leukemia (CLL / SLL)
      • Mantle cell lymphoma
      • Follicular lymphoma
      • Marginal zone B cell lymphoma
      • Extranodal MALT type
      • Hairy cell leukemia
      • Plasmacytoma / plasma cell myeloma
      • Diffuse large B cell lymphoma (DLBCL)
      • Burkitt lymphoma
    • T / NK cell lymphomas
      • T cell acute lymphoblastic lymphoma (ALL)
      • T cell CLL
      • Mycosis fungoides / Sézary syndrome
      • Peripheral T cell lymphoma
      • Angioimmunoblastic T cell lymphoma
      • Enteropathy associated intestinal T cell lymphoma
      • Hepatosplenic T cell lymphoma
      • Anaplastic large cell lymphoma (ALCL)
      • Extranodal NK / T cell lymphoma, nasal type
Rhabdomyosarcoma (RMS)[74][75][76][77][78][79][80][81][82][83]
  • MyoD1 and PIK3CA mutation (sclerosing and spindle cell RMS)
  • Most common translocation is t(2;13)(q35;q14), causingPAX3'FOXO1 gene fusion (alveolar RMS)
  • t(1;13)(p36;q14), causingPAX7'FOXO1 gene fusion
  • Embryonal RMS is associated with:
    • Loss of heterozygosity (LOH) at 11p15 locus (site of IGF-2 gene)
    • Other genes at 11p15.5 locus:
      • H19
      • CDKN1C
      • HOTS
  • Other mutations include pRb, TP53, GLI, CDKN2A, CDKN2B, RAS, FGFR4, PIK3CA, CTNNB1 [beta-catenin] and NF1 genes
  • VGLL2andNCOA2rearrangements
  • Gene fusions include VGLL2-CITED2, VGLL2-NC0A2, TEAD1-NCOA2, PAX3-NCOA2, PAX3-NCOA2, and SRF-NCOA2.
  • Further gene mutations include:
    • RAS
    • RB1
    • PTCH
    • MDM2
    • CDK4
    • MYCN
    • Basic helix-loop-helix [bHLH]
Histologic classification:
  • Embryonal RMS comprises of:
    • Rhabdomyoblasts arranged in sheets and large nests, with infrequent intermixed fusiform cells
    • Myofilaments with cross-striations
  • Botryoid (sarcoma botryoides) and spindle cell (leiomyomatous) RMS:
    • "Grape-like" gross appearance of the tumor
    • Polypoid mass grows beneath an epithelial surface, with dense subepithelial aggregates of rhabdomyoblasts (the so-called "cambrium" layer)
  • Sclerosing and spindle cell RMS
  • Alveolar RMS comprises of:
    • Fibrovascular septae lined with densely packed ovoid to round tumor cells separated by pseudo-alveolar spaces (vaguely resemble pulmonary alveoli)
    • "Loosely adherent" rhabdomyoblasts shed into these pseudo-alveolar spaces
  • Anaplastic RMS comprises of:
    • Large hyperchromatic nuclei with atypical bizarre mitotic figures
    • Nuclear size is threefold larger than that of adjacent "typical" tumor cells
Positive for:
  • Actin
  • Myosin
  • Desmin
  • Myoglobin
  • Z-band protein
  • Myogenic differentiation 1 (MyoD1)

Maybe positive for:

  • Cytokeratin
  • Synaptophysin
  • Neuron-specific enolase
  • S-100 protein
  • Malignant soft tissue tumor
  • Metastatic
  • In utero radiation exposure
  • Accelerated in utero growth
  • Low socioeconomic status
  • Antibiotics receival soon after birth
  • Recreational drugs usage during pregnancy
  • Neurofibromatosis
  • Li-Fraumeni syndrome
  • Beckwith-Wiedemann syndrome
  • Costello syndrome
  • Head and neck (orbit, parameningeal sites including middle ear, nasal cavity, paranasal sinuses, nasopharynx, infratemporal fossa, scalp, parotid gland, oral cavity, pharynx, thyroid and parathyroid glands)
  • Genitourinary tract (bladder, prostate, or the male or female genital tracts)
  • Sarcoma botryoides (urinary bladder wall, vagina, nasopharynx)
  • Extremity
  • Trunk
  • Chest wall
  • Perineal-perianal region
  • Biliary tract
  • Liver
  • Brain
  • Trachea
  • Heart
  • Breast
  • Ovary
  • Proptosis
  • Ophthalmoplegia
  • Nasal, aural, or sinus obstruction with or without a mucopurulent or sanguineous discharge
  • Localized, painless enlarging mass
  • Hematuria
  • Large pelvic mass
  • Urinary obstruction
  • Urinary frequency
  • Constipation
  • Mucosanguineous vaginal discharge
  • Polypoid mass protruding from vagina
  • Scrotal or inguinal enlargement (paratesticular tumors)
Histology of RMS similar to that of other childhood small round blue cell tumors involving bone and soft tissue such as:
  • Lymphoma
  • Small cell osteosarcoma
  • Mesenchymal chondrosarcoma
  • Ewing sarcoma family of tumors (EFT)
Liposarcoma[84][85][86][87][88][89][90][91][92][93] Atypical lipomatous tumor/well differentiated liposarcoma and dedifferentiated liposarcoma are associated with:
  • Presence of a large/giant marker chromosome and/or ring chromosomes at 12q13-15 region
  • Amplification of this chromosome region rich in protooncogenes, including CHOP, CDK4, MDM2, HMGI-C, GLI, SAS, OS1, HMGA2 and OS9

Myxoid liposarcoma is associated with:

  • t(12:16)(q13;p11) - CHOP(DDIT3) / FUS or t(12;22)(q13;q22) - CHOP(DDIT3) / EWS

Pleomorphic liposarcoma is associated with:

  • Complex karyotypic aberrations
Well-differentiated liposarcoma:
  • Sclerosing liposarcoma (distinctive stromal cells distributed across the tissue, associated with lipoblasts filled with multiple vacuoles, and collagenous background of fibrillary appearance)
  • Adipocytic liposarcoma (adipocytes with different cell sizes, hyperchromasia, and nuclear atypia. Fibrous septa containing hyperchromatic stromal cellssurrounding adipocytes)
  • Inflammatory liposarcoma (heavy chronic inflammatory infiltrate composed of different lympho-plasmacytic aggregates)
  • Spindle cell lipocarcinoma (proliferation of neural-like spindle cells organized in a fibrous structure containing lipoblasts)

De-differentiated liposarcoma:

  • Myxoid liposarcoma ( non-homogenous appearance with cystic and solid components)
  • Round Cell liposarcoma ( small, round, or spindle cells with sparse eosinophilic and granular cytoplasm and large nuclei,scattered lipoblasts and areas of necrosis)
  • Pleiomorphic liposarcoma (pleomorphic cells with enlarged round to bizarre nuclei)
Atypical lipomatous tumor/well differentiated liposarcoma is positive for:
  • MDM2
  • CDK4
  • p16
  • S100 (stains adipocytes and lipoblasts)
  • Round cell liposarcoma metstasizes to retroperitoneum, pleural cavity, soft tissue, or pelvis and lungs (poor prognosis)
  • Retroperitoneum
  • Esophagus
  • Bowel
  • Mediastinum
_
Leiomyosarcoma[94][95][96][97][98][99][100][101][102] Positive for:
  • HHF35 (90%)
  • Alpha-smooth muscle actin (90%)
  • Vimentin
  • Desmin (75%)
  • H-caldesmon
  • PTAH (stains myofibrils)
  • Keratin (30%)
  • ER (usually in uterine and female retroperitoneal tumors)
  • S100 (occasionally weak staining)
  • EMA (may be focal)
  • CD34

Negative for:

  • CD117
  • Uterus
  • Abdomen
  • Esophagus
  • Rectum
  • Skin / subcutis
  • Retroperitoneum
  • Extremities
  • Large vessels (inferior vena cava, saphenous vein, femoral vein, pulmonary artery, femoral artery)
  • Superficial or deep soft tissues
  • Bone
  • Breast
  • Colon
  • Epididymis
  • Mediastinum
  • Lungs
_
Neurofibroma[103][104][105][106][107][108][109][106][110][111][112] Can be sporadic or as a part of Neurofibromatosis 1 and 2
  • NF1 gene located at chromosomal region 17q11.2, codes for neurofibromin
  • Functional part of neurofibromin GAP (or GTPase-activating protein) accelerates the conversion of the active GTP-bound RAS to its inactive GDP-bound form
  • Loss of RAS control leads to increased activity of other signaling pathways including RAF, ERK1/2, PI3K, PAK, MAPK, SCF/c-kit and mTOR-S6 kinase
  • Made of nerve fibers, schwann cells (cells that cover the nerve fibers), blood vessels, inflammatory white blood cells (mast cells), and connective tissue (fibroblasts and loose material called extra cellular matrix)
Positive for:
  • S100
  • CD34 (focal)
  • Factor XIIIa (focal)

Negative for:

  • EMA (except in plexiform neurofibromas)
  • Cutaneous neurofibromas are always benign
  • Diffuse neurofibromas can become malignant
  • Neurofibromatosis 1
  • Neurofibromatosis 2 (multiple neurofibromas, meningiomas of the brain or spinal cord, and ependymomas of the spinal cord)
  • Anywhere in body
  • Scalp (diffuse neurofibroma)
  • Soft masses/bumps on or under skin (internal or superficial)
  • Transient itching (mast cells release histamine)
  • Transient pain
  • Numbness and tingling in the affected area
  • Severe bleeding (sign of tumor growth)
  • Physical disfiguration
  • Cognitive disability
  • Stinging
  • Neurological deficits
  • Changes in movement (clumsiness in the hands, trouble walking
  • Changes in bowel or bladder function (a sense of urgency when urinating, bowel or bladder incontinence)
  • Scoliosis (an abnormal curvature of the spine, if the tumor creates muscular imbalance or erodes bones of the spine)
Types of neurofibromas in NF1:
  • Diffuse neurofibromas
  • Cutaneous or Dermal neurofibromas
  • Intramuscular neurofibromas
  • Plexiform neurofibromas
  • Intraneural
Nodular fasciitis[113][114][115][116][117][118][119][120][121][122]
  • Balanced translocation t(17;22)(p13;q13) resulting in MYH9-USP6 gene fusion
  • Histologically vast array of patterns
  • Fibroblasts, spindle-shaped cells found in connective tissue
  • Myofibroblasts, large cells with an appearance between fibroblasts and smooth muscle tissue
  • Sub-membranous "tram track" pattern characteristic of myofibroblasts on immunostaining
  • Short C or S-shaped fascicles or cartwheel formations
  • Feathery appearance cells, with holes or tears in the tissue
  • Visible chromosomes in cells during cell division
  • Fine, pale, and even-looking chromatin
  • Inflammation, accelerated mitotic index with normal mitoses
  • Non-pleomorphic cells with high rate of mitosis
  • Essentially spindle cell proliferation
  • Stroma is rich in collagen and/or myxoid ground substance
Positive for:
  • Smooth muscle actin
  • Muscle specific actin
  • Vimentin
  • Calponin
  • CD68

Negative for:

  • S100
  • Desmin
  • Keratin
  • CD34
  • Caldesmon
  • ALK
  • p53
  • Benign
  • Reparative process secondary to trauma
  • Anywhere in body
  • Arms (34%)
  • Flexor forearm (27%)
  • Head and neck region (24%)
  • Trunk (chest, back) (21%)
  • Thigh (17%)
  • Legs (14%)
  • Upper arm (12%)
  • Hands (rarely)
  • Bladder
  • Breast
  • Cervix
  • Intra-articular
  • Prostate
  • Vagina
  • Vulva
  • Solitary firm non-painful mass
  • Oval or round in shape with irregular margins
  • Tender (maybe)
Also known as:
  • Nodular pseudosarcomatous fasciits
  • Subcutaneous pseudosarcomatous fibromatosis
  • Pseudosarcomatous fasciitis
Hypertrophic scars
  • Overexpression of growth factors such as:
  • TGF-beta
  • VEGF
  • CTGF
  • Decreased production of matrix metalloproteinases
  • Increased numbers of PDGF receptors on fibroblasts
  • Over-activation of signals for insulin-like growth factor-1
  • Decreased fibroblast apoptosis rate
  • Increased expression of thymic stromal lymphopoietin
  • Increased fibrocyte activation via stromal cell-derived factor-1
  • Genes in four susceptibility loci on chromosomes 1q41, 3q22.3-23, and 15q21.3
  • Excess collagen formation with varying numbers of fibroblasts and myofibroblasts
  • Collagen fibers are arranged in a wavy pattern predominantly oriented parallel to the epithelial surface
  • Nodular structures containing myofibroblasts and vertically aligned vessels
_
  • Benign
  • Frequent complication of burn injuries
  • Piercings
  • Cuts
  • Surgical wounds
  • Lacerations

Adverse wound healing factors at the injury site such as:

  • Infection (acne, folliculitis, chicken pox, and vaccinations)
  • Excessive tension
  • Milder than keloids
  • Don’t grow beyond the boundaries of the original skin injury
  • Cosmetic disfigurement
  • Pruritis
  • Pain
  • Functional impairment (from contracture or mechanical irritation)
  • Loss of temperature regulation
  • Dry skin
  • Neuropathic pain
Hypertrophic scars can be classified as:
  • Mature scar
  • Immature scar
  • Linear, hypertrophic scar (surgical/traumatic)
  • Widespread, hypertrophied scar (burn)
Keloids[123][124][125][126]
  • Epigenetic alteration in fibroblast DNA and acetylation of histone proteins
  • Overexpression of growth factors such as:
    • TGF-beta
    • VEGF
    • CTGF
  • Decreased production of matrix metalloproteinases
  • Increased numbers of PDGF receptors on fibroblasts
  • Over-activation of signals for insulin-like growth factor-1
  • Decreased fibroblast apoptosis rate
  • Increased expression of thymic stromal lymphopoietin
  • Increased fibrocyte activation via stromal cell-derived factor-1
  • Genes in following susceptibility loci on chromosomes:
    • 1q41
    • 3q22.3-23
    • 15q21.3
    • 2q23
    • 7p11
    • 10q23.31
  • In Japanese population, 4 SNP loci (rs873549, rs1511412, rs940187, and rs8032158) in 3 chromosomal regions (1q41, 3q22.3–23, and 15q21.3) exhibit significant associations with keloids
  • Hyalinized collagen bundles
  • Excess collagen formation with varying numbers of fibroblasts and myofibroblasts
  • Hypocellular zones of fibrous tissue containing thickened, glassy, eosinophilic collagen bundles
_
  • Benign
  • Minor injuries
  • Insect bites
  • Pimples
  • Earlobe piercings

Adverse wound healing factors at the injury site such as:

  • Infection
  • Inflammation
  • Excessive tension
  • Excessive motion (such as in injuries over a joint),
  • Wound left to heal without stitches

Keloids may be associated with rare inherited syndromes such as:

  • Rubinstein-Taybi syndrome
  • Goeminne syndrome
  • Any part of body having injury
  • Upper chest
  • Shoulders
  • Upper back
  • Head and neck (especially on ears)
  • Cosmetic disfigurement
  • Raised, reddish nodules
  • Skin pigmentation
  • Itchiness
  • Redness
  • Unusual sensations
  • Pain
  • Functional impairment
  • Keloid is Greek for "crab claw"
  • Extend beyond the borders of the original wound
  • Regress spontaneously
  • Recur after excision
  • Darkly pigmented people/African-American, Asians (Han Chinese, Japanese) are more prone to form keloids

Keloids can be prevented by using:

  • Pressure dressing
  • Silicone gel pad
  • Paper tape over the injury site for 23-24hours per day

Keloids can be classified as:

  • Minor keloid
  • Major keloid
Primitive neuroectodermal tumor (PNET)[127][128][129]
  • EWS / FLI1 fusion product by RT-PCR due to t(11;22)(q24/q22;q12) (90%)
  • p53 tumor suppressor gene mutations
  • Small blue cell tumor
  • Round hyperchromatic cells
  • Abundant mitotic figures
  • Homer Wright rosettes
  • Fibrosis
  • Neurosecretory granules on electron microscopy
Positive for:
  • CD99
  • FLI1
  • PAS+ diastase sensitive (glycogen)
  • Vimentin
  • Neuron specific enolase

Negative for:

  • Cytokeratin (usually)
  • Desmin
  • WT1
  • GFAP
  • PAX2
  • Malignant neural crest tumor
  • Highly aggressive (rapid death within 1 year)
  • Metastases to lung, pleura, bone and liver
  • CNS PNET: Intracranial (cerebral hemisphere)
  • Peripheral PNET: kidneys
Also known as:
  • CNS PNET
  • Askin tumor
  • Peripheral neuroepithelioma
  • Ependymoblastoma

WHO classified PNET into 3 subtypes:

  • Central primitive neuroectodermal tumors (PNETs)
  • Neuroblastomas
  • Peripheral primitive neuroectodermal tumors (pPNETs)

Peripheral PNET (pPNET) is now thought to be virtually identical to Ewing sarcoma

Reference

  1. Economou, Athanasios; Pitta, Xanthi; Andreadis, Efstathios; Papapavlou, Leonidas; Chrissidis, Thomas (2011). "Desmoid tumor of the abdominal wall: a case report". Journal of Medical Case Reports. 5 (1): 326. doi:10.1186/1752-1947-5-326. ISSN 1752-1947.
  2. Kasper B, Ströbel P, Hohenberger P (2011). "Desmoid tumors: clinical features and treatment options for advanced disease". Oncologist. 16 (5): 682–93. doi:10.1634/theoncologist.2010-0281. PMC 3228186. PMID 21478276.
  3. Carlson JW, Fletcher CD (2007). "Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature". Histopathology. 51 (4): 509–14. doi:10.1111/j.1365-2559.2007.02794.x. PMID 17711447.
  4. 4.0 4.1 Wu X, Petrovic V, Torode IP, Chow CW (2009). "Low grade fibromyxoid sarcoma: problems in the diagnosis and management of a malignant tumour with bland histological appearance". Pathology. 41 (2): 155–60. doi:10.1080/00313020802579276. PMID 19152188.
  5. 5.0 5.1 Bartuma H, Möller E, Collin A, Domanski HA, Von Steyern FV, Mandahl N; et al. (2010). "Fusion of the FUS and CREB3L2 genes in a supernumerary ring chromosome in low-grade fibromyxoid sarcoma". Cancer Genet Cytogenet. 199 (2): 143–6. doi:10.1016/j.cancergencyto.2010.02.011. PMID 20471519.
  6. 6.0 6.1 Wehrli BM, Weiss SW, Yandow S, Coffin CM (2001). "Gardner-associated fibromas (GAF) in young patients: a distinct fibrous lesion that identifies unsuspected Gardner syndrome and risk for fibromatosis". Am J Surg Pathol. 25 (5): 645–51. PMID 11342777.
  7. 7.0 7.1 Coffin CM, Hornick JL, Fletcher CD (2007). "Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases". Am J Surg Pathol. 31 (4): 509–20. doi:10.1097/01.pas.0000213393.57322.c7. PMID 17414097.
  8. Swartz RD (2009). "Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment". Am J Kidney Dis. 54 (3): 546–53. doi:10.1053/j.ajkd.2009.04.019. PMID 19515472.
  9. Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL (2011). "MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma". Am J Surg Pathol. 35 (5): 733–41. doi:10.1097/PAS.0b013e318210c268. PMID 21415703.
  10. Lee AF, Yip S, Smith AC, Hayes MM, Nielsen TO, O'Connell JX (2011). "Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature". Hum Pathol. 42 (11): 1804–9. doi:10.1016/j.humpath.2011.01.023. PMID 21658743.
  11. Brasanac D, Dzelatovic NS, Stojanovic M (2013). "Giant cystic superficial low-grade fibromyxoid sarcoma". Ann Diagn Pathol. 17 (2): 222–5. doi:10.1016/j.anndiagpath.2011.09.001. PMID 22136982.
  12. Vernon SE, Bejarano PA (2006). "Low-grade fibromyxoid sarcoma: a brief review". Arch Pathol Lab Med. 130 (9): 1358–60. doi:10.1043/1543-2165(2006)130[1358:LFSABR]2.0.CO;2. PMID 16948525.
  13. Lane KL, Shannon RJ, Weiss SW (1997). "Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma". Am J Surg Pathol. 21 (12): 1481–8. PMID 9414192.
  14. Nielsen GP, Selig MK, O'Connell JX, Keel SB, Dickersin GR, Rosenberg AE (1999). "Hyalinizing spindle cell tumor with giant rosettes: a report of three cases with ultrastructural analysis". Am J Surg Pathol. 23 (10): 1227–32. PMID 10524523.
  15. Hanau CA, Miettinen M (1995). "Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites". Hum Pathol. 26 (4): 440–9. PMID 7705824.
  16. de Saint Aubain Somerhausen N, Rubin BP, Fletcher CD (1999). "Myxoid solitary fibrous tumor: a study of seven cases with emphasis on differential diagnosis". Mod Pathol. 12 (5): 463–71. PMID 10349983.
  17. Cranshaw IM, Gikas PD, Fisher C, Thway K, Thomas JM, Hayes AJ (2009). "Clinical outcomes of extra-thoracic solitary fibrous tumours". Eur J Surg Oncol. 35 (9): 994–8. doi:10.1016/j.ejso.2009.02.015. PMID 19345055.
  18. England DM, Hochholzer L, McCarthy MJ (1989). "Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases". Am J Surg Pathol. 13 (8): 640–58. PMID 2665534.
  19. Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE; et al. (2012). "Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model". Mod Pathol. 25 (9): 1298–306. doi:10.1038/modpathol.2012.83. PMID 22575866.
  20. van Houdt WJ, Westerveld CM, Vrijenhoek JE, van Gorp J, van Coevorden F, Verhoef C; et al. (2013). "Prognosis of solitary fibrous tumors: a multicenter study". Ann Surg Oncol. 20 (13): 4090–5. doi:10.1245/s10434-013-3242-9. PMID 24052313.
  21. Chmielecki J, Crago AM, Rosenberg M, O'Connor R, Walker SR, Ambrogio L; et al. (2013). "Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors". Nat Genet. 45 (2): 131–2. doi:10.1038/ng.2522. PMC 3984043. PMID 23313954.
  22. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS; et al. (2013). "Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing". Nat Genet. 45 (2): 180–5. doi:10.1038/ng.2509. PMC 3654808. PMID 23313952.
  23. Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE; et al. (2013). "Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein". Acta Neuropathol. 125 (5): 651–8. doi:10.1007/s00401-013-1117-6. PMID 23575898.
  24. Coffin, Cheryl M.; Hornick, Jason L.; Zhou, Holly; Fletcher, Christopher D.M. (2007). "Gardner Fibroma: A Clinicopathologic and Immunohistochemical Analysis of 45 Patients With 57 Fibromas". The American Journal of Surgical Pathology. 31 (3): 410–416. doi:10.1097/01.pas.0000213348.65014.0a. ISSN 0147-5185.
  25. Dahl, Nathan A.; Sheil, Amy; Knapke, Sarah; Geller, James I. (2016). "Gardner Fibroma". Journal of Pediatric Hematology/Oncology. 38 (5): e154–e157. doi:10.1097/MPH.0000000000000493. ISSN 1077-4114.
  26. Schäfer M, Kadmon M, Schmidt W, Treiber I, Moog U, Sutter C; et al. (2016). "Neonatal Gardner Fibroma Leads to Detection of Familial Adenomatous Polyposis: Two Case Reports". European J Pediatr Surg Rep. 4 (1): 17–21. doi:10.1055/s-0036-1582443. PMC 5177561. PMID 28018803.
  27. Zarkavelis G, Petrakis D, Pavlidis N (2015). "Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy". Clin Transl Oncol. 17 (10): 757–62. doi:10.1007/s12094-015-1315-x. PMID 26055339.
  28. Navarrete A, Momblán D, Almenara R, Lacy A (2017). "Giant Gastric Gastrointestinal Stromal Tumor (GIST)". J Gastrointest Surg. 21 (1): 202–204. doi:10.1007/s11605-016-3196-x. PMID 27384431.
  29. Scherjon S, Lam WF, Gelderblom H, Jansen FW (2009). "Gastrointestinal stromal tumor in pregnancy: a case report". Case Rep Med. 2009: 456402. doi:10.1155/2009/456402. PMC 2745024. PMID 19763238.
  30. Acín-Gándara D, Pereira-Pérez F, Castaño-Pascual A, Durán-Poveda M, Antequera-Pérez A, Miliani-Molina C (2012). "Gastrointestinal stromal tumors: diagnosis and treatment". Cir Cir. 80 (1): 44–51. PMID 22472152.
  31. Lanzafame S, Minutolo V, Caltabiano R, Minutolo O, Marino B, Gagliano G; et al. (2006). "About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor". Pathol Res Pract. 202 (2): 119–23. doi:10.1016/j.prp.2005.08.013. PMID 16413690.
  32. Coffin CM, Watterson J, Priest JR, Dehner LP (1995). "Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases". Am J Surg Pathol. 19 (8): 859–72. PMID 7611533.
  33. 33.0 33.1 Wenig BM, Devaney K, Bisceglia M (1995). "Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm". Cancer. 76 (11): 2217–29. PMID 8635024.
  34. Ramachandra S, Hollowood K, Bisceglia M, Fletcher CD (1995). "Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases". Histopathology. 27 (4): 313–23. PMID 8847061.
  35. Häusler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B (2003). "Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review". Hum Pathol. 34 (3): 253–62. doi:10.1053/hupa.2003.35. PMID 12673560.
  36. 36.0 36.1 Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA (2005). "Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors". Am J Surg Pathol. 29 (10): 1348–55. PMID 16160478.
  37. Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R; et al. (2006). "Inflammatory myofibroblastic tumors". J Surg Oncol. 94 (5): 385–91. doi:10.1002/jso.20516. PMID 16967468.
  38. Coffin CM, Dehner LP, Meis-Kindblom JM (1998). "Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations". Semin Diagn Pathol. 15 (2): 102–10. PMID 9606802.
  39. Berardi RS, Lee SS, Chen HP, Stines GJ (1983). "Inflammatory pseudotumors of the lung". Surg Gynecol Obstet. 156 (1): 89–96. PMID 6336632.
  40. Durst AL, Freund H, Rosenmann E, Birnbaum D (1977). "Mesenteric panniculitis: review of the leterature and presentation of cases". Surgery. 81 (2): 203–11. PMID 835091.
  41. Kipfer RE, Moertel CG, Dahlin DC (1974). "Mesenteric lipodystrophy". Ann Intern Med. 80 (5): 582–8. PMID 4499963.
  42. Monahan DW, Poston WK, Brown GJ (1989). "Mesenteric panniculitis". South Med J. 82 (6): 782–4. PMID 2660295.
  43. Parra-Davila E, McKenney MG, Sleeman D, Hartmann R, Rao RK, McKenney K; et al. (1998). "Mesenteric panniculitis: case report and literature review". Am Surg. 64 (8): 768–71. PMID 9697910.
  44. Kelly JK, Hwang WS (1989). "Idiopathic retractile (sclerosing) mesenteritis and its differential diagnosis". Am J Surg Pathol. 13 (6): 513–21. PMID 2658633.
  45. Emory TS, Monihan JM, Carr NJ, Sobin LH (1997). "Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity?". Am J Surg Pathol. 21 (4): 392–8. PMID 9130985.
  46. OGDEN WW, BRADBURN DM, RIVES JD (1965). "MESENTERIC PANNICULITIS: REVIEW OF 27 CASES". Ann Surg. 161: 864–75. PMC 1409094. PMID 14295938.
  47. Khachaturian T, Hughes J (1988). "Mesenteric panniculitis". West J Med. 148 (6): 700–1. PMC 1026221. PMID 3176478.
  48. Daskalogiannaki M, Voloudaki A, Prassopoulos P, Magkanas E, Stefanaki K, Apostolaki E; et al. (2000). "CT evaluation of mesenteric panniculitis: prevalence and associated diseases". AJR Am J Roentgenol. 174 (2): 427–31. doi:10.2214/ajr.174.2.1740427. PMID 10658720.
  49. Akram S, Pardi DS, Schaffner JA, Smyrk TC (2007). "Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients". Clin Gastroenterol Hepatol. 5 (5): 589–96, quiz 523-4. doi:10.1016/j.cgh.2007.02.032. PMID 17478346.
  50. Sharma P, Yadav S, Needham CM, Feuerstadt P (2017). "Sclerosing mesenteritis: a systematic review of 192 cases". Clin J Gastroenterol. 10 (2): 103–111. doi:10.1007/s12328-017-0716-5. PMID 28197781.
  51. van der Hulst RW, Rauws EA, Tytgat GN (1995). "Mesenteritis secondary to the use of a pneumatic jackhammer". Eur J Gastroenterol Hepatol. 7 (6): 573–5. PMID 7552643.
  52. Mathew J, McKenna F, Mason J, Haboubi NY, Borghol M (2004). "Sclerosing mesenteritis with occult ileal perforation: report of a case simulating extensive intra-abdominal malignancy". Dis Colon Rectum. 47 (11): 1974–7. PMID 15622594.
  53. Horton KM, Lawler LP, Fishman EK (2003). "CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease". Radiographics. 23 (6): 1561–7. doi:10.1148/rg.1103035010. PMID 14615565.
  54. Papadaki HA, Kouroumalis EA, Stefanaki K, Roussomoustakaki M, Daskalogiannaki ME, Reppa D; et al. (2000). "Retractile mesenteritis presenting as fever of unknown origin and autoimmune haemolytic anaemia". Digestion. 61 (2): 145–8. doi:10.1159/000007748. PMID 10705180.
  55. Vidarsson B, Matthíasson P, Agnarsson BA, Onundarson PT (2002). "Mesenteric panniculitis presenting with autoimmune haemolytic anaemia". Acta Haematol. 107 (1): 35–7. doi:10.1159/000046627. PMID 11818670.
  56. Vernace MA, Bellucci AG, Mossey RT, Susin M, Mailloux LU, Wilkes BM; et al. (1996). "Minimal change nephropathy associated with sclerosing mesenteritis". Nephron. 73 (3): 473–6. doi:10.1159/000189113. PMID 8832610.
  57. Dor AM, Kohler JL, Aubrespy P, Scheiner C, Pizzi M, Lebreuil G (1982). "[Mesenteric panniculitis, an unusual initial stage of acute lupus erythematosus in a ten-year old girl (author's transl)]". Arch Anat Cytol Pathol. 30 (2): 121–4. PMID 7103574.
  58. Sauvaget F, Piette JC, Galezowski N, Jouanique C, Chapelon C, Blétry O; et al. (1993). "[Relapsing polychondritis and mesenteric panniculitis: apropos of 2 cases]". Rev Med Interne. 14 (4): 253–6. PMID 8378657.
  59. Arroyo-Ávila M, Vilá LM (2014). "Limited systemic sclerosis initially presenting with mesenteric panniculitis". BMJ Case Rep. 2014. doi:10.1136/bcr-2014-206961. PMC 4202032. PMID 25326572.
  60. Garrido A, Verdejo C, Márquez JL, Giráldez A, Trigo C, Belda O (2008). "[Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease]". Gastroenterol Hepatol. 31 (4): 221–4. PMID 18405487.
  61. Vaglio, A.; Maritati, F. (2016). "Idiopathic Retroperitoneal Fibrosis". Journal of the American Society of Nephrology. 27 (7): 1880–1889. doi:10.1681/ASN.2015101110. ISSN 1046-6673.
  62. Vaglio A, Salvarani C, Buzio C (2006). "Retroperitoneal fibrosis". Lancet. 367 (9506): 241–51. doi:10.1016/S0140-6736(06)68035-5. PMID 16427494.
  63. ORMOND JK (1948). "Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process". J Urol. 59 (6): 1072–9. PMID 18858051.
  64. van Bommel EF (2002). "Retroperitoneal fibrosis". Neth J Med. 60 (6): 231–42. PMID 12365466.
  65. Scheel PJ, Feeley N (2009). "Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation". Medicine (Baltimore). 88 (4): 202–7. doi:10.1097/MD.0b013e3181afc439. PMID 19593224.
  66. Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R; et al. (2011). "Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial". Lancet. 378 (9788): 338–46. doi:10.1016/S0140-6736(11)60934-3. PMID 21733570.
  67. Palmisano A, Urban ML, Corradi D, Cobelli R, Alberici F, Maritati F; et al. (2015). "Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?". Rheumatology (Oxford). 54 (11): 2004–9. doi:10.1093/rheumatology/kev225. PMID 26106209.
  68. Uibu T, Oksa P, Auvinen A, Honkanen E, Metsärinne K, Saha H; et al. (2004). "Asbestos exposure as a risk factor for retroperitoneal fibrosis". Lancet. 363 (9419): 1422–6. doi:10.1016/S0140-6736(04)16100-X. PMID 15121404.
  69. Koep L, Zuidema GD (1977). "The clinical significance of retroperitoneal fibrosis". Surgery. 81 (3): 250–7. PMID 841463.
  70. Graham JR, Suby HI, LeCompte PR, Sadowsky NL (1966). "Fibrotic disorders associated with methysergide therapy for headache". N Engl J Med. 274 (7): 359–68. doi:10.1056/NEJM196602172740701. PMID 5903120.
  71. UTZ DC, ROOKE ED, SPITTELL JA, BARTHOLOMEW LG (1965). "RETROPERITONEAL FIBROSIS IN PATIENTS TAKING METHYSERGIDE". JAMA. 191: 983–5. PMID 14257741.
  72. Goenka AH, Shah SN, Remer EM (2012). "Imaging of the retroperitoneum". Radiol Clin North Am. 50 (2): 333–55, vii. doi:10.1016/j.rcl.2012.02.004. PMID 22498446.
  73. Goldoni M, Bonini S, Urban ML, Palmisano A, De Palma G, Galletti E; et al. (2014). "Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study". Ann Intern Med. 161 (3): 181–8. doi:10.7326/M13-2648. PMID 25089862.
  74. H. M. Maurer, M. Beltangady, E. A. Gehan, W. Crist, D. Hammond, D. M. Hays, R. Heyn, W. Lawrence, W. Newton & J. Ortega (1988). "The Intergroup Rhabdomyosarcoma Study-I. A final report". Cancer. 61 (2): 209–220. PMID 3275486. Unknown parameter |month= ignored (help)
  75. H. M. Maurer, E. A. Gehan, M. Beltangady, W. Crist, P. S. Dickman, S. S. Donaldson, C. Fryer, D. Hammond, D. M. Hays & J. Herrmann (1993). "The Intergroup Rhabdomyosarcoma Study-II". Cancer. 71 (5): 1904–1922. PMID 8448756. Unknown parameter |month= ignored (help)
  76. W. Crist, E. A. Gehan, A. H. Ragab, P. S. Dickman, S. S. Donaldson, C. Fryer, D. Hammond, D. M. Hays, J. Herrmann & R. Heyn (1995). "The Third Intergroup Rhabdomyosarcoma Study". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13 (3): 610–630. doi:10.1200/JCO.1995.13.3.610. PMID 7884423. Unknown parameter |month= ignored (help)
  77. Michael C. G. Stevens, Annie Rey, Nathalie Bouvet, Caroline Ellershaw, Francoise Flamant, Jean Louis Habrand, H. Basil Marsden, Helene Martelli, Jose Sanchez de Toledo, Richard D. Spicer, David Spooner, Marie Jose Terrier-Lacombe, Adrian van Unnik & Odile Oberlin (2005). "Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23 (12): 2618–2628. doi:10.1200/JCO.2005.08.130. PMID 15728225. Unknown parameter |month= ignored (help)
  78. S. R. Months & R. B. Raney (1986). "Rhabdomyosarcoma of the head and neck in children: the experience at the Children's Hospital of Philadelphia". Medical and pediatric oncology. 14 (5): 288–292. PMID 3784981.
  79. J. Hicks & C. Flaitz (2002). "Rhabdomyosarcoma of the head and neck in children". Oral oncology. 38 (5): 450–459. PMID 12110339. Unknown parameter |month= ignored (help)
  80. E. Shapiro & D. Strother (1992). "Pediatric genitourinary rhabdomyosarcoma". The Journal of urology. 148 (6): 1761–1768. PMID 1433603. Unknown parameter |month= ignored (help)
  81. W. Jr Lawrence, D. M. Hays & T. E. Moon (1977). "Lymphatic metastasis with childhood rhabdomyosarcoma". Cancer. 39 (2): 556–559. PMID 837339. Unknown parameter |month= ignored (help)
  82. W. Jr Lawrence, E. A. Gehan, D. M. Hays, M. Beltangady & H. M. Maurer (1987). "Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II)". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 5 (1): 46–54. doi:10.1200/JCO.1987.5.1.46. PMID 3543238. Unknown parameter |month= ignored (help)
  83. E. S. Wiener, J. R. Anderson, J. I. Ojimba, T. E. Lobe, C. Paidas, R. J. Andrassy, R. B. Raney, S. J. Qualman, S. S. Donaldson, H. M. Maurer, M. P. Link, W. M. Crist & H. E. Grier (2001). "Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?". Seminars in pediatric surgery. 10 (3): 146–152. PMID 11481652. Unknown parameter |month= ignored (help)
  84. Khin Thway, Rashpal Flora, Chirag Shah, David Olmos & Cyril Fisher (2012). "Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors". The American journal of surgical pathology. 36 (3): 462–469. doi:10.1097/PAS.0b013e3182417330. PMID 22301498. Unknown parameter |month= ignored (help)
  85. J. Rosai, M. Akerman, P. Dal Cin, I. DeWever, C. D. Fletcher, N. Mandahl, F. Mertens, F. Mitelman, A. Rydholm, R. Sciot, G. Tallini, H. Van den Berghe, W. Van de Ven, R. Vanni & H. Willen (1996). "Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group)". The American journal of surgical pathology. 20 (10): 1182–1189. PMID 8827023. Unknown parameter |month= ignored (help)
  86. Dal Cin, Paola; Kools, Patrick; Sciot, Raf; De Wever, Ivo; Van Damme, Boudewijn; Van de Ven, Wim; Van Den Berghe, Herman (1993). "Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors". Cancer Genetics and Cytogenetics. 68 (2): 85–90. doi:10.1016/0165-4608(93)90001-3. ISSN 0165-4608.
  87. Dei Tos, Angelo P.; Doglioni, Claudio; Piccinin, Sara; Sciot, Raf; Furlanetto, Alberto; Boiocchi, Mauro; Dal Cin, Paola; Maestro, Roberta; Fletcher, Christopher D. M.; Tallini, Giovanni (2000). "Coordinated expression and amplification of theMDM2,CDK4, andHMGI-C genes in atypical lipomatous tumours". The Journal of Pathology. 190 (5): 531–536. doi:10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W. ISSN 0022-3417.
  88. Dei Tos, A (2000). "Liposarcoma: New entities and evolving concepts". Annals of Diagnostic Pathology. 4 (4): 252–266. doi:10.1053/adpa.2000.8133. ISSN 1092-9134.
  89. M. D. Kraus, L. Guillou & C. D. Fletcher (1997). "Well-differentiated inflammatory liposarcoma: an uncommon and easily overlooked variant of a common sarcoma". The American journal of surgical pathology. 21 (5): 518–527. PMID 9158675. Unknown parameter |month= ignored (help)
  90. P. Argani, F. Facchetti, G. Inghirami & J. Rosai (1997). "Lymphocyte-rich well-differentiated liposarcoma: report of nine cases". The American journal of surgical pathology. 21 (8): 884–895. PMID 9255251. Unknown parameter |month= ignored (help)
  91. H. L. Evans (1979). "Liposarcoma: a study of 55 cases with a reassessment of its classification". The American journal of surgical pathology. 3 (6): 507–523. PMID 534388. Unknown parameter |month= ignored (help)
  92. A. P. Dei Tos, T. Mentzel, P. L. Newman & C. D. Fletcher (1994). "Spindle cell liposarcoma, a hitherto unrecognized variant of liposarcoma. Analysis of six cases". The American journal of surgical pathology. 18 (9): 913–921. PMID 8067512. Unknown parameter |month= ignored (help)
  93. D. C. Dahlin, K. K. Unni & T. Matsuno (1977). "Malignant (fibrous) histiocytoma of bone--fact or fancy?". Cancer. 39 (4): 1508–1516. PMID 192432. Unknown parameter |month= ignored (help)
  94. Laura M. 3rd Arnold, Sudeep D. Burman & Albert H. O-Yurvati (2010). "Diagnosis and management of primary pulmonary leiomyosarcoma". The Journal of the American Osteopathic Association. 110 (4): 244–246. PMID 20430913. Unknown parameter |month= ignored (help)
  95. Wilkinson, N; Rollason, T P (2001). "Recent advances in the pathology of smooth muscle tumours of the uterus". Histopathology. 39 (4): 331–341. doi:10.1046/j.1365-2559.2001.01300.x. ISSN 0309-0167.
  96. S. W. Bell, R. L. Kempson & M. R. Hendrickson (1994). "Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases". The American journal of surgical pathology. 18 (6): 535–558. PMID 8179071. Unknown parameter |month= ignored (help)
  97. Launonen, V.; Vierimaa, O.; Kiuru, M.; Isola, J.; Roth, S.; Pukkala, E.; Sistonen, P.; Herva, R.; Aaltonen, L. A. (2001). "Inherited susceptibility to uterine leiomyomas and renal cell cancer". Proceedings of the National Academy of Sciences. 98 (6): 3387–3392. doi:10.1073/pnas.051633798. ISSN 0027-8424.
  98. McClain, Kenneth L.; Leach, Charles T.; Jenson, Hal B.; Joshi, Vijay V.; Pollock, Brad H.; Parmley, Richard T.; DiCarlo, Frederick J.; Chadwick, Ellen Gould; Murphy, Sharon B. (1995). "Association of Epstein–Barr Virus with Leiomyosarcomas in Young People with AIDS". New England Journal of Medicine. 332 (1): 12–18. doi:10.1056/NEJM199501053320103. ISSN 0028-4793.
  99. Fang, Zhiwei; Matsumoto, Seiichi; Ae, Keisuke; Kawaguchi, Noriyoshi; Yoshikawa, Hideki; Ueda, Takafumi; Ishii, Takeshi; Araki, Nobuhito; Kito, Masashi (2004). "Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan". Journal of Orthopaedic Science. 9 (3): 242–246. doi:10.1007/s00776-004-0768-5. ISSN 0949-2658.
  100. Futuri, S.; Donohoe, K.; Spaccavento, C.; Yudelman, I. (2014). "Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy". Case Reports. 2014 (oct14 1): bcr2014205240–bcr2014205240. doi:10.1136/bcr-2014-205240. ISSN 1757-790X.
  101. Lynch, Henry T.; Deters, Carolyn A.; Hogg, David; Lynch, Jane F.; Kinarsky, Yulia; Gatalica, Zoran (2003). "Familial sarcoma". Cancer. 98 (9): 1947–1957. doi:10.1002/cncr.11743. ISSN 0008-543X.
  102. Yu, C.-L.; Tucker, M. A.; Abramson, D. H.; Furukawa, K.; Seddon, J. M.; Stovall, M.; Fraumeni, J. F.; Kleinerman, R. A. (2009). "Cause-Specific Mortality in Long-Term Survivors of Retinoblastoma". JNCI Journal of the National Cancer Institute. 101 (8): 581–591. doi:10.1093/jnci/djp046. ISSN 0027-8874.
  103. Rodriguez, Fausto J.; Folpe, Andrew L.; Giannini, Caterina; Perry, Arie (2012). "Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems". Acta Neuropathologica. 123 (3): 295–319. doi:10.1007/s00401-012-0954-z. ISSN 0001-6322.
  104. Choi, Kwangmin; Komurov, Kakajan; Fletcher, Jonathan S.; Jousma, Edwin; Cancelas, Jose A.; Wu, Jianqiang; Ratner, Nancy (2017). "An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system". Scientific Reports. 7 (1). doi:10.1038/srep43315. ISSN 2045-2322.
  105. Liao, Chung-Ping; Booker, Reid C.; Brosseau, Jean-Philippe; Chen, Zhiguo; Mo, Juan; Tchegnon, Edem; Wang, Yong; Clapp, D. Wade; Le, Lu Q. (2018). "Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis". Journal of Clinical Investigation. 128 (7): 2848–2861. doi:10.1172/JCI99424. ISSN 0021-9738.
  106. 106.0 106.1 Staser, K.; Yang, F.-C.; Clapp, D. W. (2010). "Mast cells and the neurofibroma microenvironment". Blood. 116 (2): 157–164. doi:10.1182/blood-2009-09-242875. ISSN 0006-4971.
  107. Muir, David; Neubauer, Debbie; Lim, Ingrid T.; Yachnis, Anthony T.; Wallace, Margaret R. (2001). "Tumorigenic Properties of Neurofibromin-Deficient Neurofibroma Schwann Cells". The American Journal of Pathology. 158 (2): 501–513. doi:10.1016/S0002-9440(10)63992-2. ISSN 0002-9440.
  108. Wilkinson, Lana M.; Manson, David; Smith, Charles R. (2004). "Best Cases from the AFIP". RadioGraphics. 24 (suppl_1): S237–S242. doi:10.1148/rg.24si035170. ISSN 0271-5333.
  109. Bernthal, Nicholas; Jones, Kevin; Monument, Michael; Liu, Ting; Viskochil, David; Randall, R. (2013). "Lost in Translation: Ambiguity in Nerve Sheath Tumor Nomenclature and Its Resultant Treatment Effect". Cancers. 5 (4): 519–528. doi:10.3390/cancers5020519. ISSN 2072-6694.
  110. Mautner, V. F.; Friedrich, R. E.; von Deimling, A.; Hagel, C.; Korf, B.; Knöfel, M. T.; Wenzel, R.; Fünsterer, C. (2003). "Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma". Neuroradiology. 45 (9): 618–625. doi:10.1007/s00234-003-0964-6. ISSN 0028-3940.
  111. Shen, M H; Harper, P S; Upadhyaya, M (1996). "Molecular genetics of neurofibromatosis type 1 (NF1)". Journal of Medical Genetics. 33 (1): 2–17. doi:10.1136/jmg.33.1.2. ISSN 1468-6244.
  112. Rubin, Joshua B.; Gutmann, David H. (2005). "Neurofibromatosis type 1 — a model for nervous system tumour formation?". Nature Reviews Cancer. 5 (7): 557–564. doi:10.1038/nrc1653. ISSN 1474-175X.
  113. Sailon AM, Cappuccino G, Hameed M, Fleegler EJ (2008). "Nodular fasciitis of the hand over the metacarpophalangeal joint: a case report". Eplasty. 8: e38. PMC 2491338. PMID 18725954.
  114. Emori, M; Shimizu, J; Murahashi, Y; Mizushima, E; Sugita, S; Hasegawa, T; Yamashita, T (2018). "Nodular fasciitis involving the palm". The Annals of The Royal College of Surgeons of England. 100 (5): e128–e131. doi:10.1308/rcsann.2018.0061. ISSN 0035-8843.
  115. Kubota, Kensuke; Okada, Seiji; Maeda, Takeshi; Matsumoto, Yoshihiro; Sakamoto, Akio; Harimaya, Katsumi; Saiwai, Hirokazu; Kumamaru, Hiromi; Oda, Yoshinao; Iwamoto, Yukihide (2012). "Extradural Nodular Fasciitis Arising in the Spinal Canal". Spine. 37 (2): E133–E137. doi:10.1097/BRS.0b013e318224568a. ISSN 0362-2436.
  116. Plaza JA, Mayerson J, Wakely PE (2005). "Nodular fasciitis of the hand: a potential diagnostic pitfall in fine-needle aspiration cytopathology". Am J Clin Pathol. 123 (3): 388–93. doi:10.1309/PWD0-HB51-1L3V-R56W. PMID 15716235.
  117. Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE (2011). "A welcome surprise: nodular fasciitis presenting as soft tissue sarcoma". J Pediatr Hematol Oncol. 33 (4): 316–9. doi:10.1097/MPH.0b013e3181e88649. PMID 20975584.
  118. Grobmyer SR, Knapik JA, Foss RM, Copeland EM, Hochwald SN (2009). "Nodular fasciitis: differential considerations and current management strategies". Am Surg. 75 (7): 610–4. PMID 19655607.
  119. Yamamoto H, Yamada N, Yamada I, Hashikawa K, Kagimoto K, Ookubo M; et al. (1998). "[A case of nodular fasciitis of the chest wall]". Kyobu Geka. 51 (3): 246–9. PMID 9528235.
  120. Chiarini L, Lo Russo L, Figurelli S, Procacci P, Rubini C, Lo Muzio L (2008). "Nodular fasciitis of the face: aesthetic considerations". Aesthetic Plast Surg. 32 (3): 560–2. doi:10.1007/s00266-008-9136-8. PMID 18330617.
  121. Oliveira AM, Chou MM (2014). "USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis". Hum Pathol. 45 (1): 1–11. doi:10.1016/j.humpath.2013.03.005. PMID 23769422.
  122. Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L; et al. (2011). "Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion". Lab Invest. 91 (10): 1427–33. doi:10.1038/labinvest.2011.118. PMID 21826056.
  123. . doi:10.4197/Med. 17-3.1 Check |doi= value (help). Missing or empty |title= (help)
  124. Russell SB, Russell JD, Trupin KM, Gayden AE, Opalenik SR, Nanney LB; et al. (2010). "Epigenetically altered wound healing in keloid fibroblasts". J Invest Dermatol. 130 (10): 2489–96. doi:10.1038/jid.2010.162. PMC 2939920. PMID 20555348.
  125. Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB (2008). "Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways". J Invest Dermatol. 128 (5): 1298–310. doi:10.1038/sj.jid.5701149. PMC 2933038. PMID 17989729.
  126. Huang, Chenyu; Murphy, George F.; Akaishi, Satoshi; Ogawa, Rei (2013). "Keloids and Hypertrophic Scars". Plastic and Reconstructive Surgery Global Open. 1 (4): e25. doi:10.1097/GOX.0b013e31829c4597. ISSN 2169-7574.
  127. Smoll NR (2012). "Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs)". Cancer. 118 (5): 1313–22. doi:10.1002/cncr.26387. PMID 21837678.
  128. Eibl RH, Kleihues P, Jat PS, Wiestler OD (1994). "A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen". Am J Pathol. 144 (3): 556–64. PMC 1887088. PMID 8129041.
  129. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991). "p53 mutations in nonastrocytic human brain tumors". Cancer Res. 51 (22): 6202–5. PMID 1933879.

Template:WikiDoc Sources